Clinical Trials Directory

Trials / Completed

CompletedNCT05550909

Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali

A Five-arm Trial Comparing Artesunate-amodiaquine and Artemether-lumefantrine-amodiaquine With or Without Single-dose Primaquine to Reduce P. Falciparum Transmission in Mali

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
100 (actual)
Sponsor
London School of Hygiene and Tropical Medicine · Academic / Other
Sex
All
Age
10 Years – 50 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to compare the gametocytocidal and transmission reducing activity of artesunate-amodiaquine (ASAQ) and artemether-lumefantrine-amodiaquine (ALAQ) with and without a single dose of 0.25mg/kg primaquine (PQ). Outcome measures will include infectivity to mosquitoes at 2, 7 and 14 days after treatment, gametocyte density throughout follow-up, and safety measures including haemoglobin density and the frequency of adverse events.

Detailed description

Full protocol available on request

Conditions

Interventions

TypeNameDescription
DRUGArtesunate-amodiaquine combinationTablets containing 50mg/135 mg or 100mg/270 mg of artesunate/amodiaquine will be administered according to weight as per manufacturer guidelines
DRUGPrimaquine PhosphateThe single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
DRUGArtemether-lumefantrineTablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines
DRUGAmodiaquineTablets containing 153 mg of amodiaquine will be administered according to weight, aiming for a dosage of approximately 10 mg (7.7-15.3mg)/kg/day, given once or twice daily (together with artemether-lumefantrine) for three days.

Timeline

Start date
2022-10-17
Primary completion
2022-12-30
Completion
2023-01-26
First posted
2022-09-22
Last updated
2024-10-01

Locations

1 site across 1 country: Mali

Source: ClinicalTrials.gov record NCT05550909. Inclusion in this directory is not an endorsement.